Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Górriz, Jose Luis, Navarro-González, Juan F, Ortiz, Alberto, Vergara, Ander, Nuñez, Julio, Jacobs-Cachá, Conxita, Martínez-Castelao, Alberto, Soler, Maria Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993197/
https://www.ncbi.nlm.nih.gov/pubmed/32003834
http://dx.doi.org/10.1093/ndt/gfz237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993197/
https://www.ncbi.nlm.nih.gov/pubmed/32003834
http://dx.doi.org/10.1093/ndt/gfz237

Ejemplares similares